Curti, Brendan D
141  Ergebnisse:
Personensuche X
?
2

Phase 1 dose-escalation study of SEA-CD40: a non-fucosylate..:

Coveler, Andrew L ; Smith, David C ; Phillips, Tycel...
Journal for ImmunoTherapy of Cancer.  11 (2023)  6 - p. e005584 , 2023
 
?
5

Phase 1, open-label, dose-escalation study on the safety, p..:

Rudin, Charles M ; Pandha, Hardev S ; Zibelman, Matthew...
Journal for ImmunoTherapy of Cancer.  11 (2023)  1 - p. e005007 , 2023
 
?
 
?
10

Intratumoral oncolytic virus V937 plus ipilimumab in patien..:

Curti, Brendan D ; Richards, Jon ; Hyngstrom, John R...
Journal for ImmunoTherapy of Cancer.  10 (2022)  12 - p. e005224 , 2022
 
?
 
?
12

Trough levels of ipilimumab in serum as a potential biomark..:

Koguchi, Yoshinobu ; Iwamoto, Noriko ; Shimada, Takashi...
Journal for ImmunoTherapy of Cancer.  9 (2021)  10 - p. e002663 , 2021
 
?
13

Multicenter, double-blind, placebo-controlled trial of sevi..:

Slingluff, Craig L ; Lewis, Karl D ; Andtbacka, Robert...
Journal for ImmunoTherapy of Cancer.  9 (2021)  10 - p. e003272 , 2021
 
?
14

Enhancing clinical and immunological effects of anti-PD-1 w..:

Curti, Brendan D ; Koguchi, Yoshinobu ; Leidner, Rom S...
Journal for ImmunoTherapy of Cancer.  9 (2021)  4 - p. e002371 , 2021
 
?
15

Long-Term Progression-Free Survival of Patients with Metast..:

Clark, Joseph I ; Curti, Brendan ; Davis, Elizabeth J...
Journal of Investigative Medicine.  69 (2021)  4 - p. 888-892 , 2021
 
1-15